| pubmed-article:19118031 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C0033578 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C0034786 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C0018270 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C0684321 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:19118031 | lifeskim:mentions | umls-concept:C1515655 | lld:lifeskim |
| pubmed-article:19118031 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19118031 | pubmed:dateCreated | 2009-1-1 | lld:pubmed |
| pubmed-article:19118031 | pubmed:abstractText | Progression to the castration-resistant state is the incurable and lethal end stage of prostate cancer, and there is strong evidence that androgen receptor (AR) still plays a central role in this process. We hypothesize that knocking down AR will have a major effect on inhibiting growth of castration-resistant tumors. | lld:pubmed |
| pubmed-article:19118031 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19118031 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19118031 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19118031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19118031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19118031 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19118031 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19118031 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19118031 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:GleaveMartin... | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:RenniePaul... | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:NelsonColleen... | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:ChengHelenH | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:MargiottiKati... | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:SnoekRobertR | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:WafaLatif ALA | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:FazliLadanL | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:WongCharmaine... | lld:pubmed |
| pubmed-article:19118031 | pubmed:author | pubmed-author:WongErica... | lld:pubmed |
| pubmed-article:19118031 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19118031 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19118031 | pubmed:volume | 15 | lld:pubmed |
| pubmed-article:19118031 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19118031 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19118031 | pubmed:pagination | 39-47 | lld:pubmed |
| pubmed-article:19118031 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:meshHeading | pubmed-meshheading:19118031... | lld:pubmed |
| pubmed-article:19118031 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19118031 | pubmed:articleTitle | In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors. | lld:pubmed |
| pubmed-article:19118031 | pubmed:affiliation | Prostate Center at Vancouver General Hospital and Department of Urologic Sciences, University of British Columbia, British Columbia, Canada. | lld:pubmed |
| pubmed-article:19118031 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19118031 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:367 | entrezgene:pubmed | pubmed-article:19118031 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:19118031 | lld:entrezgene |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19118031 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19118031 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19118031 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19118031 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:19118031 | lld:pubmed |
